ANNIVERSARY REVIEW: Octreotide, 40 years later
- PMID: 31398712
- DOI: 10.1530/EJE-19-0074
ANNIVERSARY REVIEW: Octreotide, 40 years later
Abstract
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the peptide.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources